Tutorials
Vertex Pharmaceuticals Inc logo

Vertex Pharmaceuticals Inc

€ 280.00 (+3.34%) Aug 5
On watch
P/E:
30.32
P/B:
6.75
Market Cap:
€ 71.89B ($ 73.31B)
Enterprise V:
€ 63.38B ($ 64.63B)
Volume:
10.00
Avg Vol (2M):
72.00
Also Trade In:
Volume:
10.00
Market Cap €:
71.89B
Market Cap $:
73.31B
PE Ratio:
30.32
Avg Vol (2-Month):
72.00
Enterprise Value €:
63.38B
Enterprise Value $:
64.63B
PB Ratio:
6.75
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website Sources Stock Report
Dataset
Financial Download Tutorials

Business Description

Vertex Pharmaceuticals Inc
NAICS : 325412 SIC : 2834
50 Northern Avenue, Boston, MA, USA, 02210
Description
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Financials (Next Earnings Date:2022-11-02 Est.)

FRA:VX1's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil €) 6,913.783
EPS (TTM) (€) 8.347
Beta 0.33
Volatility % 28.53
14-Day RSI 55.53
14-Day ATR (€) 4.855136
20-Day SMA (€) 279.6175
12-1 Month Momentum % 65.88
52-Week Range (€) 151.56 - 292.8
Shares Outstanding (Mil) 255.76

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 6
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Vertex Pharmaceuticals Inc Filings

Document Form Filing Date
No Filing Data